Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

计划入组 346 人 · 首次发布于 2012 年 11 月 9 日

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

计划入组 82 人 · 首次发布于 2008 年 3 月 5 日

Rasburicase in Tumor Lysis Syndrome

计划入组 33 人 · 首次发布于 2006 年 3 月 14 日

Leigh syndrome therapeutic(Leigh syndrome)

O2L-001

Tumor ncoantigen

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

RETT SYNDROME RESEARCH TRUST

United States

Phase IIb/III Trial Assesses Tumor Lysis Syndrome Risk with Venetoclax Combinations in CLL

Sonrotoclax Plus Zanubrutinib Shows Promise in Relapsed/Refractory Mantle Cell Lymphoma with 78% Response Rate

Survey Reveals Challenges in Venetoclax Adoption for CLL Treatment in Community Settings